Gotowa bibliografia na temat „Vaccins ADN”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Vaccins ADN”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Vaccins ADN"
Ladenheim, Ruth. "Les vaccins à ADN nu". Biofutur 1995, nr 145 (maj 1995): 14. http://dx.doi.org/10.1016/0294-3506(95)80125-1.
Pełny tekst źródłaPitard, Bruno. "Nanotaxi® pour les vaccins ARN et ADN". médecine/sciences 35, nr 10 (październik 2019): 749–52. http://dx.doi.org/10.1051/medsci/2019143.
Pełny tekst źródłaQUENTEL, C., M. BREMONT i H. POULIQUEN. "La vaccination chez les poissons d’élevage". INRAE Productions Animales 20, nr 3 (7.09.2007): 233–38. http://dx.doi.org/10.20870/productions-animales.2007.20.3.3463.
Pełny tekst źródłaParis, Robert, Robert A. Kuschner, Leonard Binn, Stephen J. Thomas, Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Robert T. Bailer, Nancy Sullivan i Richard A. Koup. "Adenovirus Type 4 and 7 Vaccination or Adenovirus Type 4 Respiratory Infection Elicits Minimal Cross-Reactive Antibody Responses to Nonhuman Adenovirus Vaccine Vectors". Clinical and Vaccine Immunology 21, nr 5 (12.03.2014): 783–86. http://dx.doi.org/10.1128/cvi.00011-14.
Pełny tekst źródłaHarro, Clayton, Xiao Sun, Jon E. Stek, Randi Y. Leavitt, Devan V. Mehrotra, Fubao Wang, Andrew J. Bett i in. "Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults". Clinical and Vaccine Immunology 16, nr 9 (15.07.2009): 1285–92. http://dx.doi.org/10.1128/cvi.00144-09.
Pełny tekst źródłaBeaty, Shannon, Natalie Collins, Nicos Karasavvas, Robert Kuschner, Jun Hang, Anima Adhikari, Irina Maljkovic Berry i in. "A Phase 1 Two-Arm, Randomized, Double-Blind, Active-Controlled Study of Live, Oral Plasmid-Derived Adenovirus Type 4 and Type 7 Vaccines in Seronegative Adults". Vaccines 11, nr 6 (12.06.2023): 1091. http://dx.doi.org/10.3390/vaccines11061091.
Pełny tekst źródła邱南昌, 邱南昌, i 張濱璿 Nan-Chang Chiu. "臺灣預防接種受害救濟制度與COVID-19疫苗". 月旦醫事法報告 67, nr 67 (maj 2022): 050–61. http://dx.doi.org/10.53106/241553062022050067004.
Pełny tekst źródłaHalstead, Scott B., i Leah Katzelnick. "COVID-19 Vaccines: Should We Fear ADE?" Journal of Infectious Diseases 222, nr 12 (12.08.2020): 1946–50. http://dx.doi.org/10.1093/infdis/jiaa518.
Pełny tekst źródłaYılmaz, Engin. "Aşı Teknolojisinde Yeni Umutlar: mRNA Aşıları". Mikrobiyoloji Bulteni 55, nr 2 (19.04.2021): 265–84. http://dx.doi.org/10.5578/mb.20219912.
Pełny tekst źródłaAppledorn, Daniel M., Yasser A. Aldhamen, Sarah Godbehere, Sergey S. Seregin i Andrea Amalfitano. "Sublingual Administration of an Adenovirus Serotype 5 (Ad5)-Based Vaccine Confirms Toll-Like Receptor Agonist Activity in the Oral Cavity and Elicits Improved Mucosal and Systemic Cell-Mediated Responses against HIV Antigens despite Preexisting Ad5 Immunity". Clinical and Vaccine Immunology 18, nr 1 (17.11.2010): 150–60. http://dx.doi.org/10.1128/cvi.00341-10.
Pełny tekst źródłaRozprawy doktorskie na temat "Vaccins ADN"
Marsac, Delphine. "Utilisation de vaccins ADN codant pour des pseudoparticules virales comme outils de présentation d'antigènes du VIH-1 et du VIS pour l'induction d'une réponse immunitaire T in vivo". Paris 5, 2004. http://www.theses.fr/2004PA05N03S.
Pełny tekst źródłaMajor histocompatibility complex class I exogenous presentation of HIV-1 particules activates specific CTL responses. We used DNA-based immunization with plasmids codingfor HIV-1 Gag particles pseudotyped with vesicular stomatitis virus glycoprotein. The presence of the VSV-G enveloppe increased the efficiency of the specific anti-Gag lysis due to a better presentation of the Gag epitopes by MHC class I and II processing pathway. We also improved the immunogenicity of DNA vaccines encoding hepatitis B surface antigen fused to antigenic domains of simian/human immunodeficiency viruses in mice and macaques rhesus. Immunization with hybrid DNA induced effector and long-lasting precursors T, cells, efficiently
Hechard, Céline. "Vaccination ADN contre la chlamydiose abortive ovine : évaluation de la protection des vaccins ADN MOMP, DnaK et GroEL dans un modèle murin d'infection". Tours, 2002. http://www.theses.fr/2002TOUR4002.
Pełny tekst źródłaRobin, Marie. "Vaccination ADN dans la leucémie aiguë promyélocytaire et étude de la réponse immune". Paris 7, 2007. http://www.theses.fr/2007PA077073.
Pełny tekst źródłaAcute promyelocytic leukemia (APL) represents 10% of all acute myeloblastic leukaemia and is characterized by a reciprocal chromosomal translocation between 15 and 17 fusing PML and the retinoid acid receptor alpha (RARalpha). Treatment with all trans-retinoid acid (ATRA) and chemotherapy induce complete remission in more than 90% of patients with APL through ATRA-induced differentiation of the leukemic cells. Unfortunately, 10 to 30% of patients relapse. The aim of our work was to test a DNA antileukemic vaccine coding for the PML-RARalpha jonction and study the specific immunogenecity in this disease. In an APL transplantable mice model, we set up a vaccine protocol using a plasmid coding for a promoter, an adjuvant (Fc fragment from tetanie toxin) and fusion protein PML-RAR. In this model, vaccinated mice had a better survival, in particular when they received vaccine and ATRA. Mechanism of for this immune response was cellular and humoral response as demonstrated by increased interferon secretion, specific APL target lysis and specific antibodies against RARalpha. In this first study, we observed that antibody production increased with time and that antibody production on day 18 was predictive for a better survival. In humans treated according to usual protocols, we also observed an antibody secretions which in half of patients, were already present at low level at diagnosis. In 9 tested patients, antibody production was increasing with time as in mice, suggesting maintenance treatment is associated with an increased production of antibody. Furthermore, 50% of patients had also anti-nuclear and anti-neutrophil cytoplasmic antibody. We conclude that DNA vaccine is an encouraging targeted immunotherapy, in particular in patients at high risk of relapse, when patients had low leukemic burden. Antibody production should continue to be evaluated through ongoing prospective immunomonitoring of patients with APL from diagnosis throughout treatment to establish whether there is a correlation between anti-RARalpha and clinical or other biological parameter
Rolland-Turner, Magali. "Développement d'un vaccin immunocontraceptif : mise au point de tests immunologiques dans le modèle vulpin et développement de vaccins ADN avec les antigènes spermatiques fSP13 et fSP8". Nancy 1, 2005. http://www.theses.fr/2005NAN11303.
Pełny tekst źródłaFaurez, Florence. "Plasmide vaccinal réplicatif chez le porc : biosécurité". Rennes 1, 2010. http://www.theses.fr/2010REN1S023.
Pełny tekst źródłaSeveral strategies to improve DNA vaccine have been studied but few studies on the biosafety of these new strategies were carried out. This thesis provides some answers on biosafety of a replicative plasmid derived from replicative elements of porcine circovirus type 2 (PCV2). The biosafety assessment of a replicative plasmid derived from viral elements include parameters such as its characterization in vitro, assessment of its effectiveness in a vaccine, its distribution in the body, the characterization of the replication of DNA, its kinetics of elimination and number of events integrated into the genome of the organism. To contribute in part to assess the biosafety of replicative plasmid, used as a plasmid vaccine, we made a panel of replicative plasmids derived from PCV2, a method determining the rate of replication of replicative plasmids and the validation protocol used in the study of distribution of plasmids in pigs
Desolme, Benoît. "Vaccination par ADN contre la toxoplasmose : application au modèle murin avec les gènes GRA4 et SAG1 de Toxoplasma gondii : stratégies d'optimisation de la protection". Tours, 1999. http://www.theses.fr/1999TOUR3804.
Pełny tekst źródłaInnocentin, Silvia. "Utilisation de bactéries lactiques recombinantes invasives comme outil novateur pour la vaccination ADN par voie muqueuse". Versailles-St Quentin en Yvelines, 2008. http://www.theses.fr/2008VERS0012.
Pełny tekst źródłaIn this study, we evaluate the potential of Lactic Acid Bacteria (LAB) as mucosal DNA vaccine delivery vectors. LAB are food-grade bacteria already used to deliver proteins at the mucosal level. We showed that Lactococcus lactis, a model LAB, can deliver a eukaryotic expression plasmid coding for a major cow’s milk allergen, beta-lactoglobulin (BLG) gene in Caco-2 cell line with subsequent expression of BLG protein by the cells. To improve DNA delivery, we used L. Lactis strains rendered invasive by expressing Listeria monocytogenes InlA or Staphylococcus aureus FnBPA genes. Both showed comparable internalization rates and ability to deliver a GFP expression plasmid: 1% of Caco-2 cells expressed GFP while no GFP was detected with non invasive strains. We then tested invasive L. Lactis as DNA vaccine carrier in two disease models of mouse: allergic response to BLG and influenza virus infection. In vitro, Caco-2 cells expressed 30-fold more BLG when co-incubated with invasive strains compared to non invasive. In vivo, intranasal administration of invasive FnBPA+ strain and non invasive strains induced a Th2 and Th1 immune responses against BLG, respectively. Intranasal administration of invasive FnBPA+ strains designed to express hemagglutinin and nucleoprotein of influenza virus was less efficient than intradermal naked DNA immunization to protect mice from viral challenge
Moussa, Maha. "Immunité et protection induites par un lentivecteur ADN innovant chez les modèles animaux de vaccination VIH-1". Thesis, Université Grenoble Alpes (ComUE), 2015. http://www.theses.fr/2015GREAV029/document.
Pełny tekst źródłaWe recently developed an innovative prototype non-integrative lentivector DNA vaccine against HIV-1 /AIDS that we tested in pilot studies using animal models of HIV vaccine. We found that a single immunization with our prototype vaccine (CAL-SHIV-IN-) allowed the implementation of potent humoral and cellular responses in all immunized macaques. In addition, both types of responses persisted over a period of 74 weeks post-immunization in absence of antigenic boost. The characterization of the above revealed that vaccine specific T cell responses included polyfunctional CD4+ and CD8+ T cells against all antigens expressed by the vaccine. Detailed phenotypic and functional examinations of these cells showed that they were composed of effector (EM) and central memory (CM) T cells. More importantly they also contained a fraction of precursor memory T cells with high proliferative capacity (PHPC). Immune responses primed by our vaccine regiment correlated with protection in all vaccinated macaques (6/6). As expected our vaccine-induced immune responses did not prevent from infection acquisition but controlled the replication of the highly pathogenic and heterologous SIVmac251 challenge given as repeated low dose by the intrarectal mucosal route. All vaccinated animals (6/6) controlled their viremia to undetectable level using conventional PCR during at least 10 months post infection (end of the experiment). We further focused on PHPC responses associated with viral control and found that these cells vigorously proliferate upon ex vivo stimulation with specific antigens in presence of the homeostatic IL-7 and IL-15 cytokines. Proliferating antigen specific cells contained a type of stem cell-like memory T cells (TSCM). These latter (TSCM) might be a major asset in favor of our lentivector and vaccination strategy due to their high capacity for self-regeneration/maintenance in absence of antigen source
Szelechowski, Marion. "Vers une réplication controlée des vecteurs dérivés de l'adénovirus canin de type 2". Paris 7, 2008. http://www.theses.fr/2008PA077186.
Pełny tekst źródłaAmong the vectors derived for vaccination purpose, those derived from adenoviruses revealed particularly hopeful results. Replicative and defective vectors have been developed from Cav2, and we were able to demonstrate their to settle a protective immune response against the transgene product both in mice and sheep. This work aims to propose an alternative vector for vaccination derived from Cav2 and characterized by an abortive or semi-replicative behavior in the transduced cells. This vector should enable the genomic replication without production of new infectious particles. It should therefore possess both replicative vectors efficacy and defective vectors security. This can be achieved by the deletion of defined viral genomic regions, in particular within the late expression region which is dispensable for the first stages of the replication cycle. To manipulate accurately the viral genome, we elaborated a transcriptional map of the late transcriptional unit of Cav2 génome. Deletion of ail or part of the targeted open reading frames were then realized, or nor sens mutation were introduced within them, by homologuous recombinaison on the wild type Cav2 genome. Then we constructed complementing cell lines expressing the viral deleted proteins, in order to produce the recombinant viral particles. Finally, the semi-replicative properties of protease deleted Cav2 were confirmed by in vitro analysis
Bernelin-Cottet, Cindy. "Développement d'un vaccin à ADN contre le virus du Syndrome Dysgénésique et Respiratoire Porcin (PRRSV)". Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLA004/document.
Pełny tekst źródłaThe Porcine Reproductive and Respiratory Syndrome (PRRS) is the most damaging infectious disease in pigs worldwide. The etiologic agent is an Arterivirus, the PRRSV, which presents a large genetic diversity. PRRSV infection is frequently associated with influenza virus co-infection. Vaccination is a highly suitable way to control these viruses. In the case of PRRSV, the most effective commercial vaccines are modified live vaccines (MLV) which induce only a partial protection against heterologous strains. In the case of the influenza virus, the available inactivated vaccines show the same weakness.With the goal to control emerging influenza and PRRSV variants, I evaluated vaccine strategies involving conserved viral antigens between strains which were targeted to antigen-presenting cells (APC) and delivered by different routes and methods.In the case of influenza virus, the targeting of conserved antigens (HA2, M2e and NP) to CD11c led to increased IFNγ T cell responses only when vaccines were delivered by the intramuscular (IM) route and had no effect on the humoral response. The intradermal route exacerbated disease following challenge whereas the IM route reduced the symptoms, the duration of viral excretion in correlation with higher anti-HA2 and anti-M2e antibody responses.In the case of PRRSV, which was my main subject, I sought to optimize the IFNγ T cell responses by using DNA vaccines encoding antigens with conserved T-epitopes between strains, and targeted to APC. Indeed, whereas viral mutants escape neutralizing antibodies, it has been proposed that the IFNγ T cell responses are instrumental for cross-protection. I showed that the broadest T cell responses were induced by DNA vaccines combined to nanoparticles PLGA (NP) injected by the intradermal route, followed by electroporation (EP) compared with EP-only, intradermal route-only or transcutaneous dissolvable microneedles. This optimal immunogenicity was associated with a high transfection level of skin cells, an accumulation of inflammatory cells, and dendritic cells mobilisation. Next I used the EP+NP method to immunize pigs with plasmids encoding conserved PRRSV antigens targeted or not to APC via CD11c or XCR1. Pigs were immunized either with repeated injections of DNA alone or with a prime-boost DNA-MLV. The DNA-MLV regimen induced improved humoral and IFNγ T cell responses compared to DNA alone or MLV alone and the APC-targeting significantly increased the humoral response but not the IFNγ T cell response. Finally, I evaluated the DNA-MLV regimen efficacy, with an applied perspective, using naked DNA without NP and delivered by EP or by a convenient needle free injection technology (PJ). In these conditions, the DNA prime did not significantly increase the IFNγ T cell response induced by the MLV, but clearly increased the humoral response with a benefit of the APC-targeting. However, the immune potentiation induced by the DNA prime did not lead to an improved protection following a heterologous challenge. The heterologous protection was not correlated to the measured humoral and IFNγ T cell responses, and neutralizing antibodies were undetectable. Thus cross-protective effectors have not been sufficiently activated by our DNA-MLV strategy and the immune correlates of protection against heterologous PRRSV are still to be identified to develop cross-protective vaccines. Finally, this work shows that the effect of APC-targeting in pigs is influenced by delivery routes and methods and by vaccine regimen such as the prime-boost DNA-MLV
Książki na temat "Vaccins ADN"
1941-, Paterson Yvonne, red. Intracellular bacterial vaccine vectors: Immunology, cell biology, and genetics. New York: Wiley-Liss, 1999.
Znajdź pełny tekst źródłaKerns, Thomas A. Jenner on trial: An ethical examination of vaccine research in the age of smallpox and the age of AIDS. Lanham, Md: University Press of America, 1997.
Znajdź pełny tekst źródłaVaccine nation: A thriller. Las Vegas, NV]: Thomas & Mercer, 2011.
Znajdź pełny tekst źródłaVijayakṛ̥ṣṇāreḍḍi, El. Jananēta: Mudraṇamādhyaṃlō vaccina kathanāla saṅkalanaṃ. Haidarābād: Spiyarheḍ Kamyūnikēṣans, 2009.
Znajdź pełny tekst źródła1965-, Vijayakr̥ṣṇāreḍḍi El, i Munisurēṣ Piḷle Ke E, red. Jananēta: Mudraṇamādhyaṃlō vaccina kathanāla saṅkalanaṃ. Haidarābād: Spiyarheḍ Kamyūnikēṣans, 2009.
Znajdź pełny tekst źródła1965-, Vijayakr̥ṣṇāreḍḍi El, i Munisurēṣ Piḷle Ke E, red. Jananēta: Mudraṇamādhyaṃlō vaccina kathanāla saṅkalanaṃ. Haidarābād: Spiyarheḍ Kamyūnikēṣans, 2009.
Znajdź pełny tekst źródła1965-, Vijayakr̥ṣṇāreḍḍi El, i Munisurēṣ Piḷle Ke E, red. Jananēta: Mudraṇamādhyaṃlō vaccina kathanāla saṅkalanaṃ. Haidarābād: Spiyarheḍ Kamyūnikēṣans, 2009.
Znajdź pełny tekst źródła1965-, Vijayakr̥ṣṇāreḍḍi El, i Munisurēṣ Piḷle Ke E, red. Jananēta: Mudraṇamādhyaṃlō vaccina kathanāla saṅkalanaṃ. Haidarābād: Spiyarheḍ Kamyūnikēṣans, 2009.
Znajdź pełny tekst źródłaCommission, Manitoba Law Reform. Compensation of vaccine-damaged children. [Winnipeg]: Manitoba, Law Reform Commission, 2000.
Znajdź pełny tekst źródłaUnited States. Public Health Service. National Vaccine Program Office. i United States. Public Health Service., red. Disease prevention through vaccine development and immunization: The U.S. National Vaccine Plan, 1994. [Rockville, Md.?]: Dept. of Health and Human Services, Public Health Service, National Vaccine Program Office, 1994.
Znajdź pełny tekst źródłaCzęści książek na temat "Vaccins ADN"
Wu, Chung-Yi, i Chi-Huey Wong. "Vaccines Vaccine". W Glycoscience: Biology and Medicine, 1529–36. Tokyo: Springer Japan, 2014. http://dx.doi.org/10.1007/978-4-431-54841-6_198.
Pełny tekst źródłaPathak, Drishya, i A. Philo Magdalene. "COVID-19 Vaccine Development and Administration in India". W Health Dimensions of COVID-19 in India and Beyond, 129–54. Singapore: Springer Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-7385-6_7.
Pełny tekst źródłade Carvalho Clímaco, Marianna, Lucas Kraemer i Ricardo Toshio Fujiwara. "Vaccine Development for Human Leishmaniasis". W Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges, 307–26. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-24355-4_14.
Pełny tekst źródłaJoon, Shikha, Rajeev K. Singla i Bairong Shen. "Vaccines and Immunoinformatics for Vaccine Design". W Advances in Experimental Medicine and Biology, 95–110. Singapore: Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-8969-7_5.
Pełny tekst źródłaMorrison, Hazel, i Helen McShane. "BCG: Past, Present and Future Direction". W Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges, 171–95. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-24355-4_8.
Pełny tekst źródłaWang, Hua. "Leprosy Vaccines: Developments for Prevention and Treatment". W Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges, 47–69. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-24355-4_4.
Pełny tekst źródłaPathak, Drishya. "COVID-19 Vaccination: A Necessitated Drive Becoming an Unsolved Puzzle". W Global Perspectives of COVID-19 Pandemic on Health, Education, and Role of Media, 193–231. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-99-1106-6_9.
Pełny tekst źródłaMisra, Pragya, i Shailza Singh. "Vaccine Design, Nanoparticle Vaccines and Biomaterial Applications". W Systems and Synthetic Immunology, 1–52. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-3350-1_1.
Pełny tekst źródłaSmith, G. L. "Recombinant Vaccinia Viruses as Live Vaccines". W Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, 362–66. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72624-8_76.
Pełny tekst źródłaKaye, Paul M., Vivak Parkash, Alison M. Layton i Charles J. N. Lacey. "The Utility of a Controlled Human Infection Model for Developing Leishmaniasis Vaccines". W Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges, 263–79. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-24355-4_12.
Pełny tekst źródłaStreszczenia konferencji na temat "Vaccins ADN"
Kumar, Vishnu, Vijay Srinivasan i Soundar Kumara. "Towards Smart Vaccine Manufacturing: A Preliminary Study During COVID-19". W ASME 2021 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2021. http://dx.doi.org/10.1115/imece2021-70516.
Pełny tekst źródłaZughaier, Susu. "High Vaccine Coverage is Crucial for Preventing the Spread of Infectious Diseases During Mass Gathering". W Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0138.
Pełny tekst źródłaCamargo, Luana Cristina, Joao Paulo Figueiro Longo, Karen Letycia Rodrigues de Paiva, Marina Mesquita Simões, Thais Bergmann i Victor Carlos Mello da Silva. "Immunotherapy vaccines for triple-negative breast cancer and its influence on the tumor microenvironment". W Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1024.
Pełny tekst źródłaTarabrin, R. E., i E. S. Pyatigorec. "BIOETHICAL ISSUES OF VACCINOMICS". W I International Congress “The Latest Achievements of Medicine, Healthcare, and Health-Saving Technologies”. Kemerovo State University, 2023. http://dx.doi.org/10.21603/-i-ic-130.
Pełny tekst źródłaZhu, Richard, i Sujata Bhatia. "Optimizing COVID-19 Vaccine Diffusion in Respiratory Mucosa through Stokes-Einstein Modeling". W 2022 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2022. http://dx.doi.org/10.1115/dmd2022-1065.
Pełny tekst źródła"What factors are related to practicing COVID-19 vaccine by population at Ghawr Al-Safi, Jordan". W International Conference on Public Health and Humanitarian Action. International Federation of Medical Students' Associations - Jordan, 2022. http://dx.doi.org/10.56950/yrrz1540.
Pełny tekst źródłaKrishnakumar, D., i K. S. Jaganathan. "Development of nasal HPV vaccine formulations". W 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685403.
Pełny tekst źródłaEraghi, Vida. "Vaccine Development against Paratuberculosis". W Socratic Lectures 8. University of Lubljana Press, 2023. http://dx.doi.org/10.55295/psl.2023.i2.
Pełny tekst źródła"ATTITUDE TO COVID-19 VACCINATION AMONG PREGNANT WOMEN: THE JORDANIAN EXPERIENCE." W International Conference on Public Health and Humanitarian Action. International Federation of Medical Students' Associations - Jordan, 2022. http://dx.doi.org/10.56950/lzes6209.
Pełny tekst źródłaSheng, Tianyi, i Xiaoli Qiu. "Scenario-based public nebulization equipment prototype design for inhaled vaccine application". W Intelligent Human Systems Integration (IHSI 2023) Integrating People and Intelligent Systems. AHFE International, 2023. http://dx.doi.org/10.54941/ahfe1002898.
Pełny tekst źródłaRaporty organizacyjne na temat "Vaccins ADN"
Byrn, Stephen, Nathaniel Milton i Kari Clase. BIRS Course: RNA Vaccine Manufacture and Assessment of Regulatory Documents for RNA Vaccines. Purdue University, sierpień 2023. http://dx.doi.org/10.5703/1288284317657.
Pełny tekst źródłaGidengil, Courtney, Matthew Bidwell Goetz, Margaret Maglione, Sydne J. Newberry, Peggy Chen, Kelsey O’Hollaren, Nabeel Qureshi i in. Safety of Vaccines Used for Routine Immunization in the United States: An Update. Agency for Healthcare Research and Quality (AHRQ), maj 2021. http://dx.doi.org/10.23970/ahrqepccer244.
Pełny tekst źródłaTull, Kerina. Social Inclusion and Immunisation. Institute of Development Studies (IDS), luty 2021. http://dx.doi.org/10.19088/k4d.2021.025.
Pełny tekst źródłaButler, Nadia, i Soha Karam. Evidence Review: COVID-19 Vaccine Acceptance by Key Influencers in the MENA Region - Teachers and Healthworkers. Institute of Development Studies (IDS), listopad 2021. http://dx.doi.org/10.19088/sshap.2021.039.
Pełny tekst źródłaSchmidt-Sane, Megan, Elizabeth Benninger, Tabitha Hrynick i Santiago Ripoll. Youth COVID-19 Vaccine Engagement in Cleveland, Ohio, United States. Institute of Development Studies, czerwiec 2022. http://dx.doi.org/10.19088/ids.2022.040.
Pełny tekst źródłaChoi, Yoojin, Nathan M. Stall, Antonina Maltsev, Chaim M. Bell, Isaac I. Bogoch, Tal Brosh, Gerald A. Evans i in. Lessons Learned from Israel’s Vaccine Rollout. Ontario COVID-19 Science Advisory Table, luty 2021. http://dx.doi.org/10.47326/ocsat.2021.02.09.1.0.
Pełny tekst źródłaPalmer, Guy, Varda Shkap, Wendy Brown i Thea Molad. Control of bovine anaplasmosis: cytokine enhancement of vaccine efficacy. United States Department of Agriculture, marzec 2007. http://dx.doi.org/10.32747/2007.7695879.bard.
Pełny tekst źródłaBatalis, Steph, i Anna Puglisi. A Shot of Resilience. Center for Security and Emerging Technology, maj 2023. http://dx.doi.org/10.51593/20230001.
Pełny tekst źródłaSchmidt-Sane, Megan, Tabitha Hrynick, Southall Community Alliance SCA, Charlie Forgacz-Cooper i Steve Curtis. Youth COVID-19 Vaccine Engagement in Ealing, London, United Kingdom. Institute of Development Studies, czerwiec 2022. http://dx.doi.org/10.19088/ids.2022.039.
Pełny tekst źródłaVallerani, Sara, Elizabeth Storer i Costanza Torre. Key Considerations: Equitable Engagement to Promote COVID-19 Vaccine Uptake among Undocumented Urban Migrants. SSHAP, maj 2022. http://dx.doi.org/10.19088/sshap.2022.013.
Pełny tekst źródła